CNS5:Volunteer Assignments and Opportunities: Difference between revisions
Created page with "Welcome! For assignments, please see the "Author" column below (highlighted blue). If empty (no name is present), please volunteer to create content for that disease! To vol..." |
Editor updated for a page on volunteer assignments |
||
| (38 intermediate revisions by 3 users not shown) | |||
| Line 2: | Line 2: | ||
For assignments, please see the "Author" column below (highlighted blue). | For assignments, please see the "Author" column below (highlighted blue). | ||
If empty (no name is present), please volunteer to create content for that disease! | If empty (no name is present), please volunteer to create content for that disease! | ||
To volunteer, please [Contact us] with your page of interest. | To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.<br /> | ||
__TOC__ | |||
==WHO Classification of Tumours of the Central Nervous System (5th Edition) Content | {| class="wikitable" style="margin:auto" | ||
|+<big>WHO Classification of Tumours of the Central Nervous System (5th Edition) Content</big> | |||
|- | |- | ||
!'''Disease'''!!'''Page Type'''!!'''Author''' | !'''Disease'''!!'''Page Type'''!!'''<span style="color:#0070C0">Author''' | ||
!'''Date Assigned to Author''' | !'''Date Assigned to Author''' | ||
!'''Target Completion Date''' | !'''Target Completion Date''' | ||
| Line 17: | Line 18: | ||
!'''Notes''' | !'''Notes''' | ||
|- | |- | ||
| | | | ||
====CHAPTER 2 (GLIOMAS, GLIONEURONAL TUMOURS, AND NEURONAL TUMOURS)==== | |||
| | |||
---- | |||
| | |||
---- | |||
| | |||
---- | |||
| | |||
---- | |||
| | |||
---- | |||
| | |||
---- | |||
| | |||
---- | |||
| | |||
---- | |||
| | |||
---- | |||
|- | |||
|[[CNS5:Astrocytoma,_IDH-mutant|Astrocytoma, IDH-mutant]] | |||
|Disease | |Disease | ||
|Meenakshi Mehrotra | |Meenakshi Mehrotra | ||
|6/25/2023 | |6/25/2023 | ||
| | | | ||
| | |COMPLETE | ||
| | | | ||
|Laveniya Satgunaseelan (LS) | |Laveniya Satgunaseelan (LS) | ||
| Line 28: | Line 50: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
|Oligodendroglioma, IDH- | |[[CNS5:Oligodendroglioma,_IDH-mutant_and_1p/19q-codeleted|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted]] | ||
|Disease | |||
|Riley Lochner (trainee); | |||
Shashi Shetty (mentor) | |||
|6/7/2022 | |6/7/2022 | ||
| | | | ||
| Line 37: | Line 62: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
|Glioblastoma, IDH- | |[[CNS5:Glioblastoma,_IDH-wildtype|Glioblastoma, IDH-wildtype]] | ||
| | |Disease | ||
| | |Jieying Wu | ||
|11/18/2025 | |||
|01/15/2026 | |||
|PENDING | |PENDING | ||
| | | | ||
|LS | |LS | ||
| | | | ||
|Moved from " | |Moved from "Glioblastoma, IDH-wildtype" to new page; 2021 template added | ||
|- | |- | ||
|Diffuse | |[[CNS5:Diffuse_astrocytoma,_MYB-_or_MYBL1-altered|Diffuse astrocytoma, MYB- or MYBL1-altered]] | ||
|Disease | |||
|Scott Smith | |||
|6/27/2023 | |6/27/2023 | ||
| | | | ||
| | |COMPLETE | ||
| | | | ||
|LS | |LS | ||
| Line 55: | Line 84: | ||
|2021 template added (page created 6/27/23) | |2021 template added (page created 6/27/23) | ||
|- | |- | ||
|Angiocentric | |[[CNS5:Angiocentric_glioma|Angiocentric glioma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 64: | Line 95: | ||
| | | | ||
|- | |- | ||
|Polymorphous | |[[CNS5:Polymorphous_low-grade_neuroepithelial_tumour_of_the_young|Polymorphous low-grade neuroepithelial tumour of the young]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 73: | Line 106: | ||
| | | | ||
|- | |- | ||
|Diffuse | |[[CNS5:Diffuse_low-grade_glioma,_MAPK_pathway-altered_|Diffuse low-grade glioma, MAPK pathway-altered]] | ||
|Disease | |||
| | |Scott Smith | ||
| | |5/3/2024 | ||
| | | | ||
|PENDING - email reminder 9/4/2025 | |||
| | | | ||
|LS | |||
| | | | ||
| | | | ||
|- | |- | ||
|Diffuse | |[[CNS5:Diffuse_midline_glioma,_H3_K27-altered|Diffuse midline glioma, H3 K27-altered]] | ||
|Disease | |||
|Laveniya Satgunaseelan | |||
| | | | ||
|12/06/2025 | |||
|PENDING | |PENDING | ||
| | | | ||
| Line 91: | Line 128: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
|Diffuse | |[[CNS5:Diffuse_hemispheric_glioma,_H3_G34-mutant|Diffuse hemispheric glioma, H3 G34-mutant]] | ||
|Disease | |||
|Xiaolin (Lynn) Hu | |||
|2/21/2022 | |2/21/2022 | ||
| | | | ||
| Line 100: | Line 139: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
|Diffuse | !'''Disease''' | ||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |||
|[[CNS5:Diffuse_paediatric-type_high-grade_glioma,_H3-wildtype_and_IDH-wildtype|Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype]] | |||
|Disease | |||
|Madina Sukhanova | |||
|10/28/2022 | |10/28/2022 | ||
| | | | ||
| Line 109: | Line 161: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
|Infant- | |[[CNS5:Infant-type_hemispheric_glioma|Infant-type hemispheric glioma]] | ||
|Disease | |||
| | |||
| | |||
| | | | ||
| | | | ||
| Line 116: | Line 171: | ||
| | | | ||
| | | | ||
|- | |- | ||
|Pilocytic | |[[CNS5:Pilocytic_astrocytoma_|Pilocytic astrocytoma]] | ||
| | |Disease | ||
| | |||
|<br /> | |||
| | |||
| | | | ||
| | | | ||
|LS | |LS | ||
| Line 127: | Line 183: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
|High- | |[[CNS5:High-grade_astrocytoma_with_piloid_features|High-grade astrocytoma with piloid features]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 136: | Line 194: | ||
| | | | ||
|- | |- | ||
|Pleomorphic | |[[CNS5:Pleomorphic_xanthoastrocytoma|Pleomorphic xanthoastrocytoma]] | ||
| | |Disease | ||
| | |Wahab Khan | ||
|15/04/2025 | |||
| | | | ||
|PENDING - email reminder 9/4/2025 | |||
| | | | ||
|LS | |LS | ||
| Line 145: | Line 205: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
|Subependymal | |[[CNS5:Subependymal_giant_cell_astrocytoma|Subependymal giant cell astrocytoma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 154: | Line 216: | ||
| | | | ||
|- | |- | ||
|Chordoid | |[[CNS5:Chordoid_glioma|Chordoid glioma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 163: | Line 227: | ||
| | | | ||
|- | |- | ||
|Astroblastoma, MN1- | |[[CNS5:Astroblastoma,_MN1-altered|Astroblastoma, MN1-altered]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 172: | Line 238: | ||
| | | | ||
|- | |- | ||
|Ganglioglioma||Disease | |[[CNS5:Ganglioglioma|Ganglioglioma]] | ||
|Disease | |||
|Leila Moayed-Aloei | |||
|6/30/2022 | |6/30/2022 | ||
| | | | ||
| Line 181: | Line 249: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
|Gangliocytoma||Disease | |[[CNS5:Gangliocytoma|Gangliocytoma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 190: | Line 260: | ||
| | | | ||
|- | |- | ||
|Desmoplastic | !'''Disease''' | ||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |||
|[[CNS5:Desmoplastic_infantile_ganglioglioma_/_desmoplastic_infantile_astrocytoma|Desmoplastic infantile ganglioglioma / desmoplastic infantile astrocytoma]] | |||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 199: | Line 282: | ||
| | | | ||
|- | |- | ||
|Dysembryoplastic | |[[CNS5:Dysembryoplastic_neuroepithelial_tumour|Dysembryoplastic neuroepithelial tumour]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 208: | Line 293: | ||
| | | | ||
|- | |- | ||
|Diffuse | |[[CNS5:Diffuse_glioneuronal_tumour_with_oligodendroglioma-like_features_and_nuclear_clusters|Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 217: | Line 304: | ||
| | | | ||
|- | |- | ||
|Papillary | |[[CNS5:Papillary_glioneuronal_tumour|Papillary glioneuronal tumour]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 226: | Line 315: | ||
| | | | ||
|- | |- | ||
|Rosette- | |[[CNS5:Rosette-forming_glioneuronal_tumour|Rosette-forming glioneuronal tumour]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 235: | Line 326: | ||
| | | | ||
|- | |- | ||
|Myxoid | |[[CNS5:Myxoid_glioneuronal_tumour|Myxoid glioneuronal tumour]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 244: | Line 337: | ||
| | | | ||
|- | |- | ||
|Diffuse | |[[CNS5:Diffuse_leptomeningeal_glioneuronal_tumour|Diffuse leptomeningeal glioneuronal tumour]] | ||
|Disease | |||
|Laveniya Satgunaseelan | |||
|9/11/2024 | |||
| | |||
|COMPLETE | |||
|8/7/2025 | |||
|LS | |||
|LS | |||
|Used for testing 9/2024 somatic template | |||
|- | |||
|[[CNS5:Multinodular_and_vacuolating_neuronal_tumour|Multinodular and vacuolating neuronal tumour]] | |||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 253: | Line 359: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Dysplastic_cerebellar_gangliocytoma_(Lhermitte-Duclos_disease)|Dysplastic cerebellar gangliocytoma (Lhermitte-Duclos disease)]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 262: | Line 370: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Central_neurocytoma|Central neurocytoma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 271: | Line 381: | ||
| | | | ||
|- | |- | ||
| | !'''Disease''' | ||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |||
|[[CNS5:Extraventricular_neurocytoma|Extraventricular neurocytoma]] | |||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 280: | Line 403: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Cerebellar_liponeurocytoma|Cerebellar liponeurocytoma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 289: | Line 414: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Supratentorial_ependymoma|Supratentorial ependymoma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 298: | Line 425: | ||
| | | | ||
|- | |- | ||
|Supratentorial | |[[CNS5:Supratentorial_ependymoma,_ZFTA_fusion-positive_|Supratentorial ependymoma, ZFTA fusion-positive]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 307: | Line 436: | ||
| | | | ||
|- | |- | ||
|Supratentorial | |[[CNS5:Supratentorial_ependymoma,_YAP1_fusion-positive|Supratentorial ependymoma, YAP1 fusion-positive]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 316: | Line 447: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Posterior_fossa_ependymoma|Posterior fossa ependymoma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 325: | Line 458: | ||
| | | | ||
|- | |- | ||
|Posterior | |[[CNS5:Posterior_fossa_group_A_(PFA)_ependymoma|Posterior fossa group A (PFA) ependymoma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 334: | Line 469: | ||
| | | | ||
|- | |- | ||
|Posterior | |[[CNS5:Posterior_fossa_group_B_(PFB)_ependymoma|Posterior fossa group B (PFB) ependymoma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 343: | Line 480: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Spinal_ependymoma|Spinal ependymoma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 352: | Line 491: | ||
| | | | ||
|- | |- | ||
|Spinal | |[[CNS5:Spinal_ependymoma,_MYCN-amplified|Spinal ependymoma, MYCN-amplified]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 361: | Line 502: | ||
| | | | ||
|- | |- | ||
| | !'''Disease''' | ||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |||
|[[CNS5:Myxopapillary_ependymoma|Myxopapillary ependymoma]] | |||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 370: | Line 524: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Subependymoma|Subependymoma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 379: | Line 535: | ||
| | | | ||
|- | |- | ||
| | | | ||
====CHAPTER 3 (CHOROID PLEXUS TUMOURS)==== | |||
| | |||
---- | |||
| | |||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | |||
---- | |||
|- | |- | ||
|Choroid | |[[CNS5:Choroid_plexus_papilloma|Choroid plexus papilloma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 397: | Line 567: | ||
| | | | ||
|- | |- | ||
|Atypical Choroid | |[[CNS5:Atypical_choroid_plexus_papilloma|Atypical choroid plexus papilloma]] | ||
|Disease | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
|[[CNS5:Choroid_plexus_carcinoma|Choroid plexus carcinoma]] | |||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 406: | Line 589: | ||
| | | | ||
|- | |- | ||
| | | | ||
====CHAPTER 4 (EMBRYONAL TUMOURS)==== | |||
| | |||
---- | |||
| | |||
---- | |||
| | |||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
|- | |- | ||
|Medulloblastoma, WNT- | |[[CNS5:Medulloblastoma,_WNT-activated|Medulloblastoma, WNT-activated]] | ||
|Disease | |||
|Lisa Lansdon, PhD (LGG trainee just finished); | |||
Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City | |||
|9/20/21 | |9/20/21 | ||
| | | | ||
| Line 424: | Line 622: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
|Medulloblastoma, SHH- | |[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-wildtype|Medulloblastoma, SHH-activated and TP53-wildtype]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 433: | Line 633: | ||
| | | | ||
|- | |- | ||
|Medulloblastoma, SHH- | |[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-mutant|Medulloblastoma, SHH-activated and TP53-mutant]] | ||
|Disease | |||
|Hannah Wollenzien | |||
|1/11/2026 | |||
| | |||
|Pending | |||
| | |||
|MS | |||
| | |||
| | |||
|- | |||
!'''Disease''' | |||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |||
|[[CNS5:Medulloblastoma,_non-WNT/non-SHH|Medulloblastoma, non-WNT/non-SHH]] | |||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 442: | Line 666: | ||
| | | | ||
|- | |- | ||
|Medulloblastoma, | |[[CNS5:Medulloblastoma,_histologically_defined|Medulloblastoma, histologically defined]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 451: | Line 677: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Atypical_teratoid/rhabdoid_tumour|Atypical teratoid/rhabdoid tumour]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 460: | Line 688: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Cribriform_neuroepithelial_tumour|Cribriform neuroepithelial tumour]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 469: | Line 699: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Embryonal_tumour_with_multilayered_rosettes|Embryonal tumour with multilayered rosettes]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 478: | Line 710: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:CNS_neuroblastoma,_FOXR2-activated|CNS neuroblastoma, FOXR2-activated]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 487: | Line 721: | ||
| | | | ||
|- | |- | ||
|CNS | |[[CNS5:CNS_tumour_with_BCOR_internal_tandem_duplication|CNS tumour with BCOR internal tandem duplication]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 496: | Line 732: | ||
| | | | ||
|- | |- | ||
|CNS | |[[CNS5:CNS_embryonal_tumour_NEC/NOS|CNS embryonal tumour NEC/NOS]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 505: | Line 743: | ||
| | | | ||
|- | |- | ||
| | | | ||
====CHAPTER 5 (PINEAL TUMOURS)==== | |||
| | |||
---- | |||
| | |||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | |||
---- | |||
|- | |- | ||
|Pineocytoma||Disease | |[[CNS5:Pineocytoma|Pineocytoma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 523: | Line 775: | ||
| | | | ||
|- | |- | ||
|Pineal | !'''Disease''' | ||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |||
|[[CNS5:Pineal_parenchymal_tumour_of_intermediate_differentiation|Pineal parenchymal tumour of intermediate differentiation]] | |||
|Disease | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
| Line 529: | Line 796: | ||
| | | | ||
| | | | ||
|- | |||
|[[CNS5:Pineoblastoma|Pineoblastoma]] | |||
|Disease | |||
|Fang Fang (trainee)+Katie Schieffer (mentor) | |||
|11/19/2025 | |||
|5/15/2026 | |||
|Pending | |||
| | |||
|LS | |||
| | | | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Papillary_tumour_of_the_pineal_region|Papillary tumour of the pineal region]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 541: | Line 819: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Desmoplastic_myxoid_tumour_of_the_pineal_region,_SMARCB1-mutant|Desmoplastic myxoid tumour of the pineal region, SMARCB1-mutant]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 550: | Line 830: | ||
| | | | ||
|- | |- | ||
| | | | ||
====CHAPTER 6 (CRANIAL AND PARASPINAL NERVE TUMOURS)==== | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | |||
---- | |||
| | |||
---- | |||
| | |||
---- | |||
|- | |- | ||
|Schwannoma||Disease | |[[CNS5:Schwannoma|Schwannoma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 568: | Line 862: | ||
| | | | ||
|- | |- | ||
|Neurofibroma||Disease | |[[CNS5:Neurofibroma|Neurofibroma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 577: | Line 873: | ||
| | | | ||
|- | |- | ||
|Perineurioma||Disease | |[[CNS5:Perineurioma|Perineurioma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 586: | Line 884: | ||
| | | | ||
|- | |- | ||
|Hybrid | |[[CNS5:Hybrid_nerve_sheath_tumours|Hybrid nerve sheath tumours]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 595: | Line 895: | ||
| | | | ||
|- | |- | ||
|Malignant | |[[CNS5:Malignant_melanotic_nerve_sheath_tumour|Malignant melanotic nerve sheath tumour]] | ||
|Disease | |||
| | | | ||
| | | | ||
| Line 603: | Line 904: | ||
| | | | ||
| | | | ||
| | |||
|- | |||
!'''Disease''' | |||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |- | ||
|Malignant | |[[CNS5:Malignant_peripheral_nerve_sheath_tumour|Malignant peripheral nerve sheath tumour]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 613: | Line 928: | ||
| | | | ||
|- | |- | ||
|Cauda | |[[CNS5:Cauda_equina_neuroendocrine_tumour_(previously_paraganglioma)|Cauda equina neuroendocrine tumour (previously paraganglioma)]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 622: | Line 939: | ||
| | | | ||
|- | |- | ||
| | | | ||
====CHAPTER 7 (MENINGIOMA)==== | |||
| | |||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | |||
---- | |||
| | |||
---- | |||
|- | |- | ||
| | |[[CNS5:Meningioma|Meningioma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 640: | Line 971: | ||
| | | | ||
|- | |- | ||
| | | | ||
====CHAPTER 8 (MESENCHYMAL, NON-MENINGOTHELIAL TUMOURS INVOLVING THE CNS)==== | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | |||
---- | |||
| | |||
---- | |||
| | |||
---- | |||
|- | |- | ||
| | |[[CNS5:Solitary_fibrous_tumour|Solitary fibrous tumour]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 658: | Line 1,003: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Haemangiomas_and_vascular_malformations|Haemangiomas and vascular malformations]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 667: | Line 1,014: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Haemangioblastoma|Haemangioblastoma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 676: | Line 1,025: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Rhabdomyosarcoma|Rhabdomyosarcoma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 685: | Line 1,036: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Intracranial_mesenchymal_tumour,_FET::CREB_fusion-positive|Intracranial mesenchymal tumour, FET::CREB fusion-positive]] | ||
|Disease | |||
| | | | ||
| | | | ||
| Line 693: | Line 1,045: | ||
| | | | ||
| | | | ||
| | |||
|- | |||
!'''Disease''' | |||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |- | ||
| | |[[CNS5:CIC-rearranged_sarcoma|CIC-rearranged sarcoma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 703: | Line 1,069: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Primary_intracranial_sarcoma,_DICER1-mutant|Primary intracranial sarcoma, DICER1-mutant]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 712: | Line 1,080: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Ewing_sarcoma|Ewing sarcoma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 721: | Line 1,091: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Mesenchymal_chondrosarcoma|Mesenchymal chondrosarcoma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 730: | Line 1,102: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Chondrosarcoma|Chondrosarcoma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 739: | Line 1,113: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Chordoma|Chordoma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 748: | Line 1,124: | ||
| | | | ||
|- | |- | ||
| | | | ||
====CHAPTER 9 (MELANOCYTIC TUMOURS)==== | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | |||
---- | |||
| | |||
---- | |||
| | |||
---- | |||
|- | |- | ||
| | |[[CNS5:Diffuse_meningeal_melanocytic_neoplasms:_Melanocytosis_and_melanomatosis|Diffuse meningeal melanocytic neoplasms: Melanocytosis and melanomatosis]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 766: | Line 1,156: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Circumscribed_meningeal_melanocytic_neoplasms:_Melanocytoma_and_melanoma|Circumscribed meningeal melanocytic neoplasms: Melanocytoma and melanoma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 775: | Line 1,167: | ||
| | | | ||
|- | |- | ||
| | | | ||
====CHAPTER 10 (HAEMATOLYMPHOID TUMOURS INVOLVING THE CNS)==== | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | |||
---- | |||
| | |||
---- | |||
| | |||
---- | |||
|- | |- | ||
| | |[[CNS5:Primary_diffuse_large_B-cell_lymphoma_of_the_CNS|Primary diffuse large B-cell lymphoma of the CNS]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 793: | Line 1,199: | ||
| | | | ||
|- | |- | ||
| | !'''Disease''' | ||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |||
|[[CNS5:Immunodeficiency-associated_CNS_lymphomas|Immunodeficiency-associated CNS lymphomas]] | |||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 802: | Line 1,221: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Lymphomatoid_granulomatosis|Lymphomatoid granulomatosis]] | ||
| | |Disease | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Intravascular_large_B-cell_lymphoma|Intravascular large B-cell lymphoma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 820: | Line 1,243: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:MALT_lymphoma_of_the_dura|MALT lymphoma of the dura]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 829: | Line 1,254: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Other_low-grade_B-cell_lymphomas_of_the_CNS|Other low-grade B-cell lymphomas of the CNS]] | ||
|Disease | |||
| | |||
| | |||
| | |||
| | | | ||
| | | | ||
| Line 835: | Line 1,264: | ||
| | | | ||
| | | | ||
|- | |||
|[[CNS5:Anaplastic_large_cell_lymphoma_(ALK+/ALK−)|Anaplastic large cell lymphoma (ALK+/ALK−)]] | |||
|Disease | |||
|Jennie Thurston | |||
|7/2/2023 | |||
| | |||
|PENDING | |||
| | | | ||
|MS | |||
| | | | ||
|2021 template added; Did not yet convert to CNS5 namespace. Should Jennie instead do the related two pages in HAEM5 of "[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma - Compendium of Cancer Genome Aberrations (ccga.io)]]" and "[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma - Compendium of Cancer Genome Aberrations (ccga.io)]]"? | |||
|- | |- | ||
| | |[[CNS5:T-cell_and_NK/T-cell_lymphomas|T-cell and NK/T-cell lymphomas]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 847: | Line 1,287: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Erdheim-Chester_disease|Erdheim-Chester disease]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 856: | Line 1,298: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Rosai-Dorfman_disease|Rosai-Dorfman disease]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 865: | Line 1,309: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Juvenile_xanthogranuloma|Juvenile xanthogranuloma]] | ||
|Disease | |||
| | | | ||
| | | | ||
| Line 873: | Line 1,318: | ||
| | | | ||
| | | | ||
| | |||
|- | |||
!'''Disease''' | |||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |- | ||
| | |[[CNS5:Langerhans_cell_histiocytosis|Langerhans cell histiocytosis]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 883: | Line 1,342: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Histiocytic_sarcoma|Histiocytic sarcoma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 892: | Line 1,353: | ||
| | | | ||
|- | |- | ||
| | | | ||
====CHAPTER 11 (GERM CELL TUMOURS)==== | |||
| | |||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | |||
---- | |||
| | |||
---- | |||
|- | |- | ||
| | |[[CNS5:Germ_cell_tumours_of_the_CNS|Germ cell tumours of the CNS]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 910: | Line 1,385: | ||
| | | | ||
|- | |- | ||
| | | | ||
====CHAPTER 12 (TUMOURS OF THE SELLAR REGION==== | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | |||
---- | |||
| | |||
---- | |||
| | |||
---- | |||
|- | |- | ||
| | |[[CNS5:Adamantinomatous_craniopharyngioma|Adamantinomatous craniopharyngioma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 928: | Line 1,417: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Papillary_craniopharyngioma|Papillary craniopharyngioma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 937: | Line 1,428: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Pituicytoma,_granular_cell_tumour_of_the_sellar_region,_and_spindle_cell_oncocytoma|Pituicytoma, granular cell tumour of the sellar region, and spindle cell oncocytoma]] | ||
|Disease | |||
| | |||
| | |||
| | | | ||
| | | | ||
| Line 944: | Line 1,438: | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Pituitary_adenoma_/_pituitary_neuroendocrine_tumour|Pituitary adenoma / pituitary neuroendocrine tumour]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 955: | Line 1,450: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Pituitary_blastoma|Pituitary blastoma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 964: | Line 1,461: | ||
| | | | ||
|- | |- | ||
| | !'''Disease''' | ||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |||
| | | | ||
====CHAPTER 13 (METASTASES TO THE CNS)==== | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | |||
---- | |||
| | |||
---- | |||
| | |||
---- | |||
|- | |- | ||
| | |[[CNS5:Metastases_to_the_brain_and_spinal_cord_parenchyma|Metastases to the brain and spinal cord parenchyma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 982: | Line 1,504: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Metastases_to_the_meninges|Metastases to the meninges]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 991: | Line 1,515: | ||
| | | | ||
|- | |- | ||
| | | | ||
====CHAPTER 14 (GENETIC TUMOUR SYNDROMES INVOLVING THE CNS)==== | |||
| | |||
---- | |||
| | |||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | | | ||
---- | |||
| | |||
---- | |||
|- | |- | ||
| | |[[CNS5:Neurofibromatosis_type_1|Neurofibromatosis type 1]] | ||
| | |Disease | ||
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|- | |||
|[[CNS5:Neurofibromatosis_type_2|Neurofibromatosis type 2]] | |||
|Disease | |||
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|- | |||
|[[CNS5:Schwannomatosis|Schwannomatosis]] | |||
|Disease | |||
| | |||
| | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Von_Hippel-Lindau_syndrome|Von Hippel-Lindau syndrome]] | ||
|Disease | |||
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|- | |||
|[[CNS5:Tuberous_sclerosis|Tuberous sclerosis]] | |||
|Disease | |||
| | | | ||
| | | | ||
| Line 1,026: | Line 1,589: | ||
| | | | ||
| | | | ||
| | |||
|- | |||
|[[CNS5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]] | |||
|Disease | |||
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|- | |||
!'''Disease''' | |||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |||
|[[CNS5:Cowden_syndrome|Cowden syndrome]] | |||
|Disease | |||
|[[DIG5:Volunteer Assignments and Opportunities|See DIG5 volunteer sheet for authorship status]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|- | |- | ||
| | |[[CNS5:Constitutional_mismatch_repair_deficiency_syndrome|Constitutional mismatch repair deficiency syndrome]] | ||
|Disease | |||
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|- | |||
|[[CNS5:Familial_adenomatous_polyposis_1|Familial adenomatous polyposis 1]] | |||
|Disease | |||
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|- | |||
|[[CNS5:Naevoid_basal_cell_carcinoma_syndrome|Naevoid basal cell carcinoma syndrome]] | |||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 1,036: | Line 1,657: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Rhabdoid_tumour_predisposition_syndrome|Rhabdoid tumour predisposition syndrome]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 1,045: | Line 1,668: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Carney_complex|Carney complex]] | ||
|Disease | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| Line 1,060: | Line 1,678: | ||
| | | | ||
| | | | ||
|- | |||
|[[CNS5:DICER1_syndrome|DICER1 syndrome]] | |||
|Disease | |||
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|- | |||
|[[CNS5:Familial_paraganglioma_syndromes|Familial paraganglioma syndromes]] | |||
|Disease | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| Line 1,070: | Line 1,700: | ||
| | | | ||
| | | | ||
|- | |||
|[[CNS5:Melanoma-astrocytoma_syndrome|Melanoma-astrocytoma syndrome]] | |||
|Disease | |||
| | | | ||
| | | | ||
| | | | ||
| Line 1,081: | Line 1,712: | ||
| | | | ||
|- | |- | ||
| | |[[CNS5:Familial_retinoblastoma|Familial retinoblastoma]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 1,090: | Line 1,723: | ||
| | | | ||
|- | |- | ||
| | !'''Disease''' | ||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |||
|[[CNS5:BAP1_tumour_predisposition_syndrome|BAP1 tumour predisposition syndrome]] | |||
|Disease | |||
| | | | ||
| | | | ||
| Line 1,098: | Line 1,743: | ||
| | | | ||
| | | | ||
| | |||
|- | |||
|[[CNS5:Fanconi_anaemia|Fanconi anaemia]] | |||
|Disease | |||
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|N/A | |||
|- | |- | ||
|ELP1- | |[[CNS5:ELP1-medulloblastoma_syndrome|ELP1-medulloblastoma syndrome]] | ||
|Disease | |||
| | |||
| | | | ||
| | | | ||
| Line 1,108: | Line 1,767: | ||
| | | | ||
|- | |- | ||
|} | |} | ||